Description

Affimed N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer immunotherapies, with operations spanning the United States, Germany, and the rest of Europe. The company's primary investigational therapy, AFM13, has successfully completed a Phase II clinical study for peripheral T-cell lymphoma. This same candidate is also currently undergoing Phase IIa clinical trials for CD30-positive lymphoma and is in Phase I trials for Hodgkin lymphoma. Beyond its lead product, Affimed is advancing several other promising pipeline compounds. AFM24, a tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptors and CD16A, is presently in Phase IIa clinical trials for the treatment of various advanced cancers. Additionally, two other innate cell engagers (ICEs) are in preclinical development: AFM28, which is being investigated for acute myeloid leukemia, and AFM32, a candidate focused on the treatment of solid tumors. Affimed N.V. has formed strategic partnerships with esteemed institutions and companies, including The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. The company also receives research funding through an agreement with The Leukemia & Lymphoma Society. Founded in 2000, Affimed N.V. was initially known as Affimed Therapeutics B.V. before officially changing its name in October 2014. Its corporate headquarters are located in Heidelberg, Germany.